# Cancer Benefits and Risks From Ozempic, Wegovy, and Other Weight Loss Drugs - Memorial Sloan Kettering Cancer Center

## Metadata
| Field | Value |
|-------|-------|
| Source | Memorial Sloan Kettering Cancer Center |
| URL | https://news.google.com/rss/articles/CBMiogFBVV95cUxQTks0QzNiVVhHb3A4QUUyN1BCQ1RXNnlINUNxdzloaUFyUzhTQ19PbG9wZnV3UEhsaWpoQ0ZycWFRTkhHLWY5N3lBcXNWSFZJSWxNMnB0eldCX1dkbF9oY1J1VDN6cW0zOGpseFJYaDVacDZ1SjdvWnpITG9iX1ZwdFBGbXIyUjJTNUFYTTA1LXQzNTd2SVdZQzB6VmZzRjBoYUE?oc=5&hl=en-US&gl=US&ceid=US:en |
| Scraped | 2025-12-29 18:01 |
| Category | GLP-1 |
| Relevance | 8/10 |
| Signal | bull |

## Investment Summary
Memorial Sloan Kettering research explores cancer-related implications of GLP-1 weight loss drugs like Ozempic and Wegovy, signaling potential broader health impacts beyond obesity treatment.

## Key Entities
Memorial Sloan Kettering Cancer Center, Novo Nordisk (Ozempic/Wegovy manufacturer), Eli Lilly (Mounjaro manufacturer)

## Dollar Amounts
None mentioned

---

## Article Content

*Full content could not be extracted. Visit URL for details.*

---

#healthcare-news #glp-1 #auto-scraped
